Lisa Argnani

Associate Professor

University of Bologna

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Lisa Argnani is an Associate Professor at the University of Bologna in Italy. Her research focuses on lymphoma treatment, particularly the efficacy of immune checkpoint inhibitors and the role of the gut microbiome in patient outcomes. She has contributed to various studies on chimeric antigen receptor T-cell therapy, allogeneic stem cell transplantation, and the management of rheumatoid arthritis following initial treatment failures.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Alen Zabotti

ITALY

View details

PIER LUIGI ZINZANI

University of Bologna

ITALY

View details

Ettore Silvagni

University of Ferrara

ITALY

View details

Marco Sebastiani

University of Modena and Reggio Emilia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lisa Argnani

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study

Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology

Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience

Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

Collaborators (4)

Alen Zabotti

PIER LUIGI ZINZANI

Ettore Silvagni

Marco Sebastiani

Make your next move.